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Abstract: Marine algae represent a prolific source of filamentous fungi for bioprospecting.
In continuation of our search for new anticancer leads from fungi derived from the brown alga Fucus
vesiculosus, an endophytic Pyrenochaetopsis sp. FVE-001 was selected for an in-depth chemical analysis.
The crude fungal extract inhibited several cancer cell lines in vitro, and the highest anticancer activity
was tracked to its CHCl3–soluble portion. A bioactivity-based molecular networking approach was
applied to C18-SPE fractions of the CHCl3 subextract to predict the bioactivity scores of metabolites
in the fractions and to aid targeted purification of anticancer metabolites. This approach led to a
rapid isolation of three new decalinoylspirotetramic acid derivatives, pyrenosetins A–C (1–3) and
the known decalin tetramic acid phomasetin (4). The structures of the compounds were elucidated
by extensive NMR, HR-ESIMS, FT-IR spectroscopy, [α]D and Mosher’s ester method. Compounds
1 and 2 showed high anticancer activity against malignant melanoma cell line A-375 (IC50 values
2.8 and 6.3 µM, respectively), in line with the bioactivity predictions. This is the first study focusing
on secondary metabolites of a marine-derived Pyrenochaetopsis sp. and the second investigation
performed on the member of the genus Pyrenochaetopsis.
Keywords: marine fungus; pyrenosetin; phomasetin; Pyrenochaetopsis sp.; Fucus vesiculosus;
bioactivity-based molecular networking; decalin tetramic acid
1. Introduction
Macroalgae (seaweeds) are regarded as holobionts due to their complex epiphytic and endophytic
microbiota [1]. Seaweed-derived fungi are emerging as a promising source of novel bioactive secondary
metabolites for marine bioprospecting. For example, plinabulin, the synthetic tert-butyl analog
of diketopiperazine halimide, which derives from the seaweed-derived fungus Aspergillus sp. [2]
is currently undergoing phase III clinical trials for treatment of non-small cell lung cancer [2,3].
Over the past decades, fungi associated with brown algal genus Fucus have gained attention as
an untapped source of fungal biodiversity [4,5]. A previous study by Flewelling et al. showed
Fucus-associated fungi to produce antimicrobial compounds [6]. Further studies have shown that
Fucus-derived fungi produced secondary metabolites belonging to diverse structural classes and
exhibited further bioactivities. For example, the culture broth of Fucus spiralis-derived fungus Phoma
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sp. yielded the polyketide 5-hydroxyramulosin and 7-methoxycoumarin, which showed anticancer,
antifungal and anti-HIV activities [7,8]. Another study by Lateff et al. (2003) reported a new,
antioxidant isobenzofuranone derivative from Epicoccum sp. associated with Fucus vesiculosus [9].
However, a systematic research exploring bioactive metabolites from fungi associated with Fucus sp. is
still missing.
Mass spectrometry-based molecular networking (MN) in conjunction with the publicly available
web-platform Global Natural Products Social Molecular Network (GNPS) serves as an automated
tool for mining large volumes of mass spectra. MN uses an untargeted metabolomics approach that
powerfully processes the tandem mass spectrometry (MS/MS) fragmentation data. It is a vector-based
workflow that calculates cosine scores (between 0 and 1) to determine the degree of similarity between
the MS2 fragments. These fragment ions (nodes) will then be organized into relational networks
depending on their similarity [10]. MN has been employed for rapid and successful dereplication
of known compounds from complex natural extracts [11,12]. Another advantage of MN is the
possibility for incorporation of additional information, such as the bioactivity data, over the network.
The bioactivity mapping or bioactivity-based MN have been effectively applied in natural product
research on both crude extracts and fractions obtained therefrom [13,14]. In the latter, a further
bioinformatic program is employed to predict the bioactivity score of molecules according to their
relative abundance in the fractions. Bioactivity-based MN (B-B MN) approach, hence assists rapid
prioritization and targeted isolation of bioactive compounds, thereby accelerating natural product
biodiscovery efforts.
Fucus vesiculosus is a habitat forming brown alga commonly found in the shallow coastal regions of
Europe. In a recent study, we profiled the surface microbiome and metabolome of the Baltic F. vesiculosus
and identified primary and secondary metabolites, including many fungal metabolites from its surface
and inner tissues by massive MN coupled with DESI-imaging mass spectrometry [15]. We also reported
the isolation and identification of epiphytic and endophytic fungal communities associated with
F. vesiculosus, and applied an OSMAC approach to assess the impact of culture conditions on chemical
space and anticancer potential of these filamentous fungi [12]. A fungal strain belonging to the order
Pleosporales showed anticancer activity with lower toxicity to non-cancerous cells when cultivated in
liquid potato dextrose medium (PDM) [12]. In the continuation of this project, we have now identified
this fungus as a Pyrenochaetopsis sp. (strain FVE-001) by building a phylogenetic tree and comparing
relationship with closely related fungal species. We further focused on isolation and characterization
of its anticancer constituents. For this aim, we applied a B-B MN workflow [14] on the C18-SPE
fractions obtained from the CHCl3 subextract of the fungus for prioritization of the active fractions
and targeted isolation of new bioactive compounds. This approach enabled rapid identification of
three new and one known decalinoyl tetramic acid derivatives, 1–4. Herein we outline the isolation,
structure elucidation and anticancer activities of the compounds 1–4.
2. Results
2.1. Strain Isolation and Identification
The endophytic fungus FVE-001 was isolated from the thallus of Fucus vesiculosus collected at Kiel
Fjord (Baltic Sea, Germany) [12]. The initial Sanger sequencing of the PCR-amplified ITS1-5.8S rRNA
gene-ITS2 region yielded a total length of 297 bp fragment, which only enabled its identification at
order level, i.e., Pleosporales [12]. In order to further confirm the taxonomic identity of the fungus,
the same genomic DNA extract was re-amplified and sequenced for ITS1-5.8S-ITS2 genes to yield a 394
bp length PCR fragment. The sequence result was subjected to NCBI Blast analysis that showed 100%
sequence similarity to Phoma sp. and 99% sequence similarity to closely related strain, Pyrenochaetopsis
microspore. In order to further validate the taxonomy of the fungus FVE-001, a phylogenetic tree was
constructed with 14 related strains from the NCBI database. As shown in Figure 1, the phylogenetic
tree suggested the fungus FVE-001 to be closely related to Phoma sp. However, in the phylogenetic
Mar. Drugs 2020, 18, 47 3 of 16
tree, FVE-001 did not cluster with the typical Phoma sp., i.e., Phoma neerlandica and Phoma herbarum.
Further investigation revealed that the closely related Phoma strains MUT 5460, MUT 5462 and
MUT 5465 (Figure 1) have now been reclassified as Pyrenochaetopsis leptospora in the UNITE database
(https://unite.ut.ee/sh/SH1525086.08FU#fndtn-panel1) [16]. This confirmed that the fungus FVE-001 to
be a Pyrenochaetopsis sp.
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2.2. Cultivation, Extraction, Bioactivity Test and Molecular Networking
Based on the results of our One-Strain-Many-Compounds (OSMAC) study [12], the fungus
Pyrenochaetopsis sp. FVE-001 was cultivated at 22 ◦C for 14 days under shaking (120 rpm) in 2 L flasks,
each containing 800 mL PDM liquid medium. The EtOAc extract of the culture broth (12 L in total)
was evaporated, and subjected to a modified Kupchan partition to yield n-hexane (KH), CHCl3 (KC)
and aqueous MeOH (KM) subextracts. All three subextracts were tested against five human cancer cell
lines (malignant melanoma A-375; lu g c rcinoma A-549; colorectal adeno arcinoma HT-29; colorectal
carcinoma HCT-116 and breast cancer MB-231), plus against non-cancerous human keratinocyte cell
HaCaT for ass ssing their cyt toxicity. The KC subextract showed the highest activity against all cancer
cell lines (>75% cell growth inhibition at 100 µg/mL) (Table S1), a d was selected for in-depth chemical
investigations. It was subjected to solid phase extraction (SPE) on a C18 Sep-Pak cartridge (10%
gradient elution from 0% to 100% methanol) to yield 11 fractions. Fractions 5–7 exhibited a promising
activity with high rates of growth inhibition (up to 99% at 100 µg/mL, Table S1). The fraction 8 showed
a moderate inhibition rate (43%) against malignant melanoma cell line A-375 while the rest of the
fractions had no activity (Table S1). In order to investigate their chemical profiles, all 11 fractions were
analyzed by tandem UPLC-QToF-MS/MS (positive ion mode) metabolomics using MN. To facilitate the
bioassay-guided isolation of anticancer metabolites, we integrated the bioactivity and the MS/MS (MS2)
data of the fractions using the B-B MN workflow [14]. Briefly, the acquired MS2 data was processed
using MZmine2 toolbox to detect and assess relative quantification of LC-MS/MS spectral features (ions)
across the chromatographic fractions. The processed data was used to calculate a bioactivity score using
the Pearson correlation coefficient (r) between feature intensity, i.e., the molecule’s relative abundance
calculated from the LC-MS peak (area under the curve) across the fraction, and the anticancer activity
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of each fraction. The nodes with higher r (>0.75) and lower p (<0.05) values indicated the presence of
most active metabolites in fractions 5–7. Since this approach only allowed using single bioactivity data
per analysis, activity results against melanoma cancer cell line A-375 was used to calculate bioactivity
scores. Finally, the processed data was analyzed on the GNPS platform and visualized by Cytoscape®.
The B-B MN of the SPE fractions obtained from the KC subextract of Pyrenochaetopsis sp. FVE-001
is displayed in Figure 2. A total of 175 nodes forming seven different chemical clusters were identified
after removal of nodes from chromatography solvents and the medium. The node size in Figure 2
indicates the statistical significance of bioactivity score, i.e., the largest nodes represent molecules
with strong Pearson correlation (r > 0.75) and a significance (p < 0.05). Since the r value has linear
correlation between the molecule’s relative abundance and the level of the bioactivity, the B-B MN
directly visualizes the relative bioactivity of the detected molecules. The relative abundance of the
detected molecules in the each fraction is shown in each node with a pie chart diagram (colors
corresponding to the bioactivity level of each fraction, i.e., red for samples with inhibition rate >90%,
pink for samples with inhibition rate 90–75%, light pink for samples with inhibition rate 75–20% and
grey for inactive samples). In total, 10.3% (18 of total 175 nodes) of molecules showed a statistically
significant bioactivity score (r > 0.75 and p < 0.05). This approach enabled us to narrow down the
potentially active metabolites to 18 nodes (out of 56 nodes) that were detected in the highly active
fractions 5–7.
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of Pyrenoch etopsis sp. FVE-001. (A) Subcluster of diketopiperazine chemical family detected in MN.
(B) Subcluster of decalin family detected in MN. 1–4: Decalinoyltetramic acid derivatives, 5: known
diketopiperazine cyclo-(leu-pro).
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A detailed analysis of the MN permitted the annotation of several fungal metabolites to different
molecular families (Figure 2). The biggest cluster with 144 nodes consisted of several subclusters
(e.g., A and B). The node with the precursor ion m/z 211.1442 ([M + H]+, C11H19N2O2) in subcluster A
showed a close MS/MS spectral matching with GNPS spectral library and was annotated as the known
diketopiperazine cyclo-(leu-pro) (5) [17]. Three related nodes in subcluster A at m/z 209.0637, 241.1498
and 237.1113 that clustered with 5 were also identified as structurally related diketopiperazines.
The subcluster B, which contains the most of the potential bioactive metabolites revealed a node
(m/z 414.2645 [M + H]+, C25H36NO4) suggestive of the known fungal metabolite phomasetin (4) [18]
(Figure 3). This was further confirmed by diagnostic MS/MS fragments corresponding to the loss of the
olefinic side chain of the decalin moiety (m/z 346.2017 and 328.1915) and the cleavage of the tetramic acid
moiety (m/z 271.2062 and 243.2113). No additional spectral annotation could be retrieved from GNPS
library for other related nodes in the subcluster B. However, detailed analysis of MS/MS fragmentation
patterns suggested that molecules in subcluster B are closely related to phomasetin (4). The subcluster
B consisted of the highest number of potentially active nodes (15 of total 18 nodes). Based on the
significant bioactivity score of nodes at m/z 412.2484 (1) ([M − H2O + H]+) and 412.2488 (2) ([M − H2O
+ H]+) (r values of 0.79, 0.93 and p values of 2.2 × 10-3 and 1.30 × 10-5, respectively) and their close
similarity to phomasetin (4), we carried out a targeted isolation of these putatively bioactive molecules.
In addition, a related molecule with m/z 428.2434 [M + H]+ (3) with low bioactivity score (r value 0.45)
was also targeted due to the high probability to be an analogue of the most active metabolites.
ar. rugs 2020, 18, x FOR PEER REVIEW 5 of 16 
 
A detailed analysis of the MN permitted the annotation of several fungal metabolites to 
different molecular families (Figure 2). The biggest cluster with 144 nodes consisted of several 
subcl sters (e.g., A and B). The node with the precursor ion m/z 211.1442 ([M + H]+, C11H19N2O2) in 
subcluster A showed a close MS/MS spectral matching with GNPS spectral library and was 
annotated as the known diketopiperazine cyclo-(leu- ro) (5) [17]. Three related nodes in subcluster 
A at m/z 209.0637, 241.1498 and 237.1113 that clustered with 5 were also identified as structurally 
related diketopiperazines. The subcluster B, which contains the most of the potential bioactive 
metabolites revealed a node (m/z 414.2645 [M + H]+, C25H36NO4) suggestive of the known fungal 
etabolite phomasetin (4) [18] (Fig re 3). This was further confirmed by diagnostic MS/MS 
fragments corresponding to the loss of the olefinic side chain of the decalin moiety (m/z 346.2017 and 
328.1915) and the cleavage of the tetra ic acid moiety (m/z 271.2062 and 243.2113). No additional 
spectral annotation could be retrieved from GNPS library for other related nodes in the subcluster B. 
However, detailed analysis of MS/MS fragmentation patterns suggested that molecules i  
subcluster B are closely related to phomasetin (4). The subcluster B consisted of the highest number 
of potentially active nodes (15 of total 18 nodes). Based on the significant bioactivity score of nodes 
at m/z 412.2484 (1) ([M − H2O + H]+) and 412.2488 (2) ([  −  + ]+) (r values of 0.79, 0.93 and p 
values of 2.2 × 10-3 and 1. 0 × 10-5, respectively) and their close similarity to phomasetin (4), we 
carried out a targeted isolation of these putatively bioactive molec les. In addition, a related 
molecule with m/z 428.2434 [M + H]+ (3) with low bioactivity score (r value 0.45) was also targeted 
due to the high probability to be an analogue f the most active metabolites. 
 
Figure 3. Chemical structures of compounds 1–4. 
2.3. Purification and Structure Elucidation 
The comprehensive analysis of the B-B MN revealed fractions 5 and 6 to have the highest 
relative abundance of targeted molecules. Based on this, fractions 5 and 6 were combined (106 mg 
altogether) and subjected to RP-HPLC separation to afford three new compounds, 1–3 (Figure 3). 
The known metabolite phomasetin (4) (Figure 3), which was previously identified by MS/MS based 
Figure 3. Chemical structures of compounds 1–4.
2.3. Purification and Structure Elucidation
The comprehensive analysis of the B-B MN revealed fractions 5 and 6 to have the highest relative
abundance of targeted molecules. Based on this, fractions 5 and 6 were combined (106 mg altogether)
and subjected to RP-HPLC separation to afford three new compounds, 1–3 (Figure 3). The known
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metabolite phomasetin (4) (Figure 3), which was previously identified by MS/MS based dereplication
(see above), was isolated from fraction 7. The chemical structure of phomasetin (4) was confirmed by
comparing its HRMS, NMR (Tables 1 and 2) and [α]D data with those reported in the literature [19].
Compound 1 was isolated as a colorless oil. HR-ESIMS spectrum of 1 contained a molecular ion
peak at m/z 430.2592 [M + H]+ consistent with the molecular formula C25H35NO5 requiring 9 degrees
of unsaturation (Figure S7). The FT-IR spectrum implied the presence of hydroxyl and carbonyl groups
(3249–3554, 1683 and 1721 cm−1, respectively) (Figure S8). The 13C-NMR data (Table 2, Figure S2)
comprised 25 carbon signals, including four olefinic carbons at δc 127.3, 128.1, 131.8 and 138.8 along
with three carbonyl groups at δC 168.6, 207.2 and 213.3. The 1H NMR and DEPT-HSQC spectra of 1
(Table 1, Figures S1 and S3) contained signals corresponding to five methyl groups, of which two are
secondary (δH 1.19, d, J = 6.4 Hz, H3-17; δH 0.90, d, J = 6.5 Hz, H3-19), one tertiary (δH 0.98, s, H3-12),
one olefinic (δH 1.73, br s, H3-18) and one being an N-methyl (δH 3.10, s, H3-7′). The DEPT-HSQC
spectrum also confirmed the presence of four diastereotopic methylene protons corresponding to
H2-7 (δH 0.86 and 1.78), H2-9 (δH 1.01 and 1.72), H2-10 (δH 1.04 and 1.42) and the oxymethylene H2-6′
(δH 4.09, dd, J = 12.2, 2.6 Hz and δH 3.92, dd, J = 12.3, 4.8 Hz). Further detected were ten complex
methine protons, six of which appearing at δH 2.57 (H-3, d, J = 11.4 Hz), δH 1.43 (H-8, m), δH 1.82
(H-6, m), δH 1.63 (H-11, m), δH 3.44 (H-13, dd, J = 11.4, 8.6 Hz) and δH 3.57 (H-5′, dd, J = 4.8, 2.6 Hz).
The seventh (oxy) methine proton appeared at δH 4.24 (H-16, m). The remaining three methine protons
were olefinic; two appeared as part of an AB system at δH 5.75 (H-14, dd, J = 15.4, 8.6 Hz) and δH 5.71
(H-15, dd J = 15.4, 4.8 Hz), while the final olefinic methine (H-5) emerged as a broad singlet at δH 5.24
(Figure S1). The 1H-1H COSY spectrum of 1 (Figure S4) led to the establishment of three spin systems.
As shown in Figure 4A, the shortest spin system belonged to a hydroxyethyl group including H-5′ and
H-6′, while the second spin system was represented by a 16-hydroxypentenyl group (H-13 to H3-17).
The largest and third COSY spin network corresponded to a substituted methylcyclohexane moiety,
starting with the secondary methyl H3-19 and ending with the olefinic H-5 (Figure 4A and Figure S4).
Diagnostic HMBC correlations (Figure 4A and Figure S5) observed from H-3 to C-2, C-4, C-11; from
H-5 to C-3, C-7 and C-11; from H-7 to C-5, C-8 and C-9 and from H-11 to C-2, C-6, C-7, C-9 and C-10
permitted the establishment of the bicyclic partial structure, i.e., the unsaturated decalin moiety (rings
A-B, Figure 4A). The olefinic methyl H3-18 was assigned to C-4 based on the substantial HMBC cross
peaks seen from H3-18 to C-4, C-5 and C-3. The secondary methyl H3-19 was already placed at C-8 by
COSY data and HMBC cross-peaks from H3-19 to C-7, C-8 and C-9 further confirmed its assignment.
The tertiary methyl H3-12 had to be attached at C-2 on the basis of multiple HMBC correlations of
H3-12 with C-1, C-2, C-3 and C-11. Additional correlations, i.e., COSY (between H-3 and H-13, H-13
and H-14) and HMBC (between H-3 with C-13, C-14 and C-15), confirmed the attachment of the
16-hydroxypentenyl side chain at C-3 of the decalin ring (Figure 4A, Figures S4 and S5). Further HMBC
correlations from H-5′ to C-2′, C-4′ and from H3-7′ to C-2′and C-5′ established the terminal N-methyl
tetramic acid structure (ring D) (Figure 4A and Figure S5). The long-range (HMBC) couplings detected
between H-13/C-3′ and H-13/C-2′ confirmed the connectivity of tetramic acid ring to decalin moiety
through a spiro carbon, C-3′ (Figure 4A and Figure S5). A key long range coupling between H3-12/C-1
and H3-12/C-2 and H-3/C-12 clearly assigned the carbonyl group (δc 213.3) at C-1. This completed the
final ring system, C (Figure 4A).
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Table 1. 1H NMR data of compounds 1–4 at 600 MHz.
No.
1 a 2 a 3 a 4 b
δH, Mult (J in Hz) δH, Mult (J in Hz) δH, Mult (J in Hz) δH, Mult (J in Hz)
1 - - - -
2 - - - -
3 2.57, d (11.4) 2.73, d (11.4) 2.66, d (11.3) 3.17, br d (9.4)
4 - - - -
5 5.24, br s 5.22, br s 5.28, br.s 5.22, br s
6 1.82, m 1.82, m 1.83, m 1.84, m
7 1.78, m 1.80, m 1.82, m 1.82, m
0.86, m 0.84, m 0.88, m 0.86, m
8 1.43, m 1.44, m 1.44, m 1.51, m
9 1.72, m 1.73, m 1.73, m 1.76, m
1.01, m 0.93, m 0.99, m 1.04, m
10 1.42, m 1.40, m 1.41, m 1.97, m
1.04, m 1.07, qd (12.8,3.4) 1.04, m 1.06, m
11 1.63, m 1.42, m 1.64, td (11.0, 2.7) 1.64 m
12 0.98, s 1.00, s 1.01, s 1.38, br s
13 3.44, dd (11.4, 8.6) 3.26, dd (11.4, 9.4) 3.57, dd (11.4, 9.8) 5.27, dd (13.6, 10.5)
14 5.75, dd (15.4, 8.6) 5.97, dd (15.3, 9.4) 6.85, dd (15.9, 9.8) 5.78, dd (14.6, 10.5)
15 5.71, dd (15.4 4.8) 5.50, dd (15.3, 8.0) 6.18, d (15.9) 5.91, t (12.8)
16 4.24, m 4.18, m - 5.56, dq (14.2, 6.8)
17 1.19, d (6.4) 1.19, d (6.2) 2.22, s 1.67, d (6.8)
18 1.73, br s 1.69, br s 1.68, br s 1.55, t (1.9)
19 0.90, d (6.5) 0.91, d (6.5) 0.90, d (6.2) 0.91, d (6.5)
2′ - - - -
3′ - - - -
4′ - - - -
5′ 3.57, dd (4.8, 2.6) 3.94, dd (2.7, 1.9) 3.61, dd (4.9, 2.7) 3.61, t (2.7)
6′ 4.09, dd (12.2, 2.6) 4.08, m 4.10, m 3.87, m
3.92, dd (12.3, 4.8) 3.86, dd (12.4, 2.7) 3.94, m 3.81, m
7′ 3.10, s 3.07, s 3.11, s 2.97, brs
6′-OH 2.74, m
a Recorded in CDCl3, b Recorded in CD3CN.
The relative configuration of the stereogenic centers within 1 was established mainly by NOESY
data (Figure 4B and Figure S6). The NOESY correlations observed between H-6/H-8, H-6/H3-12,
H3-12/H-3 and H-11/H-13 revealed the trans junction of the decalin ring, the α-orientation of H-3,
H-6, H-8, H3-12 and the β-orientation of H-11, H-13 and H3-19 methyl group (Figure 4B). The large
coupling constant (J14,15 = 15.4 Hz) and the NOESY correlation detected between H-13 and H-15
indicated the E-geometry of the double bond at ∆14(15). The NOE correlations and the distances (Å)
between relevant protons on the Chem3D optimized model of 1 assisted the assignment of the relative
stereochemistry at C-5′ in the tetramic acid portion (Figure 4B, Table S3). The NOE cross-peaks detected
between H-5′/H-15 (distance 2.96 Å) and H-5′/H-17 (distance 3.28 Å) indicated H-5′ to be β-oriented.
The absolute configuration of C-16 was determined by Mosher’s ester method [20]. The compound
1 was converted to 16-(S)-MTPA methyl ester (6) and 16-(R)-MTPA methyl ester (7) using (S)- and
(R)-MTPA chloride (Figures S25 and S26). The differences of 1H NMR chemical shifts around C-16 of 6
and 7 were measured (Table S2, Figure S29). The results of ∆δ (δS–δR) for H-14 (0.08), H-15 (0.07) and
H3-17 (−0.08) suggested the absolute configuration at C-16 to be S. Thus, we propose the trivial name
pyrenosetin A for compound 1.
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Table 2. 13C NMR data of compounds 1–4 at 150 MHz.
Position
1 a 2 a 3 a 4 b
δC δC δC δC
1 213.3 (C) 209.8 (C) 212.1 (C) 197.6 (C)
2 54.8 (C) 54.1 (C) 54.7 (C) 49.9 (C)
3 53.6 (CH) 52.8 (CH) 53.6 (CH) 50.2 (CH)
4 131.8 (C) 132.3 (C) 130.9 (C) 132.4 (C)
5 128.1 (CH) 127.6 (CH) 128.8 (CH) 127.1 (CH)
6 37.6 (CH) 37.6 (CH) 37.6 (CH) 40.1 (CH)
7 41.9 (CH2) 42.0 (CH2) 41.8 (CH2) 43.1 (CH2)
8 33.0 (CH) 32.9 (CH) 32.9 (CH) 34.3 (CH)
9 35.3 (CH2) 35.3 (CH2) 35.2 (CH2) 36.6 (CH2)
10 25.3 (CH2) 25.3 (CH2) 25.2 (CH2) 29.0 (CH2)
11 37.4 (CH) 38.0 (CH) 37.4 (CH) 40.6 (CH)
12 15.0 (CH3) 15.2 (CH3) 15.2 (CH3) 14.2 (CH3)
13 51.5 (CH) 51.0 (CH) 50.6 (CH) 131.6 (CH)
14 127.3 (CH) 130.5 (CH) 144.4 (CH) 133.4 (CH)
15 138.8 (CH) 137.8 (CH) 133.9 (CH) 132.1 (CH)
16 67.9 (CH) 69.0 (CH) 197.6 (C) 129.2 (CH)
17 23.5 (CH3) 22.9 (CH3) 27.6 (CH3) 18.1 (CH3)
18 24.2 (CH3) 23.9 (CH3) 23.7 (CH3) 22.5 (CH3)
19 22.4 (CH3) 22.4 (CH3) 22.4 (CH3) 22.7 (CH3)
2′ 168.6 (C) 168.6 (C) 167.8 (C) 178.1 (C)
3′ 73.1 (C) 73.8 (C) 72.7 (C) 101.6 (C)
4′ 207.2 (C) 205.0 (C) 206.4 (C) 191.5 (C)
5′ 69.8 (CH) 69.4 (CH) 69.8 (CH) 68.8 (CH)
6′ 60.3 (CH2) 58.3 (CH2) 60.3 (CH2) 59.6 (CH2)
7′ 28.3 (CH3) 27.7 (CH3) 28.5 (CH3) 27.4 (CH3)
a Recorded in CDCl3, b Recorded in CD3CN.
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Compound 2 was isolated as an optically active colorless oil. Its molecular formula C25H35NO5
deduced by HR-ESIMS (m/z 452.2401 [M + Na]+) was found to be the same as 1 (Figure S15). A close
inspection of its FT-IR, 1D and 2D NMR spectra (Figures S9–S14 and S16) revealed that 2 had the
same 2D structure as 1. As depicted in Tables 1 and 2, 1D NMR spectra of 2 however contained slight
changes in chemical shifts of H-14 (1 δH 5.75 and 2 δH 5.97) and C-14 (1 δc 127.3 and 2 δC 130.5); H-15
(1 δH 5.71 and 2 δH 5.50) and C-15 (1 δc 138.8 and 2 δC 137.8); and H-16 (1 δH 4.24 and 2 δH 4.18) and
C-16 (1 δc 67.9 and 2 δC 69.0). These differences were indicative of an opposite (R) stereochemistry at
C-16. The absolute configuration of C-16 was investigated by Mosher’s method. The chemical shift
differences [∆δ(δS-δR)] in the 1H-NMR of the MTPA esters (8 and 9) for H-14 (−0.01), H-15 (−0.13) and
Mar. Drugs 2020, 18, 47 9 of 16
H3-17 (+0.04) suggested a 16-R absolute configuration, which was opposite to 1 (Table S2, Figures S27,
S28 and S30). The absence of any NOESY correlation between H-5′and H-15 or between H-5′and H-17
suggested the α-orientation of H-5′. The distances calculated on the 3D structure of compound 2 (with
both α- and β-epimers of H-5′) (Table S3) supported this assignment. Based on the NOESY spectrum
(Figure S14), the relative configuration of all other chiral centers within 2 was identified to be the same
as in compound 1. We suggest the trivial name pyrenosetin B for compound 2.
HR-ESIMS analysis of compound 3 revealed a molecular ion (m/z 428.2434 [M + H]+) that
corresponded to a molecular formula C25H33NO5 (Figure S23). This requires 10 degrees of unsaturation.
The FT-IR, 1D and 2D NMR data of 3 closely resembled compounds 1 and 2 (Figures S17–S22 and S24).
The two most striking differences were the absence of H-16 oxymethine resonance in the 1H-NMR
spectrum of 2, and the appearance of an additional carbonyl singlet at δC 197.6 (C-16) in its 13C-NMR
spectrum (Tables 1 and 2, Figures S17 and S18). This clearly suggested 3 to be an oxidized analog of 1
and 2. The conversion of the secondary methyl group H3-17 into a highly deshielded singlet at δH 2.22
(Table 1) indicated that the hydroxyl group at C-16 was replaced by a ketone function. The remarkable
shift of H-14 and H-15 protons to downfield up to +0.8 and 1.0 ppm, respectively, further supported
this assumption (Table 1). Clear HMBC correlations from H-14, H-15 and H3-17 to C-16 provided the
final proof for the presence of a carbonyl function at C-16. The planar structure of 3 was confirmed
by detailed analysis of 1H, 13C, DEPT-HSQC, COSY and HMBC data (Figures S17–S22). The relative
configuration of the chiral centers at C-3, C-6, C-8, C-11, C-2, C-13, C-3′ and C-5′ within 3 was deduced
to be the same as in 2 by analyzing its NOESY spectrum (Figure S22) and distances between proton
pairs H-5′/H-15 and H-5′/H-17 (Table S3). We suggest the trivial name pyrenosetin C for compound 3.
2.4. Biological Activity of Compounds 1–4
Compounds 1–4 were tested against the human malignant melanoma cancer cells (A-375).
As shown in Table 3, compounds 1 and 2 showed the highest anticancer activity with IC50 values of 2.8
and 6.3 µM, respectively. Compound 3 and the known metabolite 4 were less potent (IC50 140.3 and
37.3 µM). The general toxicity of the isolated metabolites was assessed against the human keratinocyte
cell line HaCaT. Interestingly the IC50 values of 1, 3 and 4 against HaCaT cells were very similar to their
IC50 values against melanoma cells, indicating them to be non-selectively toxic. However, compound 2
exerted lower toxicity towards HaCaT cells (IC50 35.0 µM) with a relatively better selectivity index
around 5.6 (calculated by dividing IC50 value against HaCaT cells / IC50 value against A-375 cells)
compared to other three fungal metabolites.
Table 3. In vitro activity of compounds 1–4 against human malignant melanoma cell line (A-375) and
non-cancerous keratinocyte cell line (HaCaT). The IC50 values are in µM. Positive control: Doxorubicin.
Compound A-375 Cells HaCaT Cells
1 2.8 (±0.0) 4.2 (±0.0)
2 6.3 (±0.0) 35.0 (±0.0)
3 140.3 (±0.9) 142.9 (±1.4)
4 37.3 (±0.1) 45.0 (±0.2)
Positive control 0.6 (±0.0) 22.1 (±2.9)
3. Discussion
Phylogenetic tree analysis confirmed the fungus FVE-001 to be a Pyrenochaetopsis sp. The genus
Pyrenochaetopsis has previously been reported as a close relative of Pyrenochaeta, which is a member of
the family Cucurbitariaceae. The genus Pyrenochaetopsis shows genetic similarity to the genus Phoma,
but their conidiogenesis is considered to be significantly different [21,22]. The chemical machinery of
the genus Pyrenochaetopsis has not received much attention so far. To our knowledge, only one chemical
study has been performed on terrestrial soil fungus Pyrenochaetopsis sp., reporting the isolation of
phomasetin (4) and two new decalinoyl tetramic acids, wakodecalines A and B [18]. A very recent study
Mar. Drugs 2020, 18, 47 10 of 16
by Kato et al. (2018) has identified the biosynthetic gene cluster of phomasetin in a Pyrenochaetopsis
sp. RK10-F058 [23]. The wakodecalines A and B showed moderate antimalarial activity against the
Plasmodium falciparum 3D7, but were inactive against cancer cell lines [18]. Phomasetin (4) has been
reported from few fungal genera, e.g., Phoma and Pyrenochaetopsis. It exerts anti-HIV and antitumor
activities against cancer cell lines such as HeLa and HL-60 [18,19]. In this study phomasetin showed
weak antitumor activity, which was associated with general toxicity.
The major drawbacks of the traditional bioassay-guided isolation process include its time
consuming nature and the re-isolation of known compounds. Molecular network-based metabolomics
is emerging as an efficient method in identification of chemical inventory of biological organisms
and dereplication of natural products from crude extracts [11,24]. In our previous work, we used
OSMAC approach to investigate chemical diversity and anticancer activity of fungi associated with
Fucus vesiculosus [12] where we mapped the anticancer activity data of large number of fungal extracts
over the MN and searched for a link between spectral molecular networks and their anticancer
activity [12]. One fungus from this study that was identified herein as Pyrenochaetopsis sp. FVE-001
(order Pleosporales) was selected for work-up, based on its anticancer activity. The combination of both
bioassay-guided fractionation and MN approaches in the form of B-B MN allowed the rapid isolation
of three new compounds 1–3. As expected, pyrenosetins A (1) and B (2) had the highest anticancer
activity, supporting the bioactivity scores obtained by B-B MN at fractionation stage. Pyrenosetin B
(2) that differs from 1 by the stereochemistry of the C-16 hydroxyl group displayed less pronounced
anticancer activity but also lower toxicity. The replacement of the OH group at C-16 with a keto
function in pyrenosetin C (3) was not favorable for bioactivity, leading to a low IC50 value against
A-375 cells. This indicates that the presence of an OH group at C-16 impacts the anticancer and toxic
potential of pyrenosetins A-C.
Compounds 1–3 possess unique decalinoylspirotetramic acid structures characterized by a
trans-decalin ring, a fused spiro system with a carbonyl unit (cyclopentanone) and a terminal tetramic
acid moiety. Bioactive natural products containing trans-decalin ring are common in fungi (e.g.,
genera Fusarium, Penicillium and Alternaria) [25], however, molecules containing a decalin ring with
a terminal tetramic acid structure linked through a spiro ring are rare in Nature. Some known
examples include fusarisetins A and B from a soil-derived Fusarium sp., fusarisetins C-D from a
marine-derived Fusarium sp. [26,27], altercrasins A-E from a sea urchin-derived Alternaria sp. [28].
Wakodecalines A and B obtained from the terrestrial soil fungus Pyrenochaetopsis sp. RK10-F058 possess
a N-methylated serine moiety instead of the terminal tetramic acid ring [18]. Interestingly some
Fusarium sp. [29] contain equisetin, the enantiomeric homolog of phomasetin, which possesses totally
opposite stereochemistry in all chiral centers. Such compounds have been proposed to be mixed
biosynthesis products of PKS and NRPS pathways [23]. Despite the structural similarities, biosynthesis
of decalin derivatives is highly controlled by stereospecific enzymes [19,30]. A recent study by Kato et
al. (2018) reported that the stereospecific enzyme fas2 determines the formation of the trans-decalin ring
in equisetin (and fusarisetin), while phm7 enzyme controls the biosynthesis of the trans-decalin ring in
the enantiomeric homolog phomasetin (4) [23]. In this study, we isolated phomasetin (4) and three
new related metabolites 1–3 from Pyrenochaetopsis sp. FVE-001. This is the first chemical study carried
out on a marine-derived Pyrenochaetopsis sp. and the second investigation performed on a member of
the genus Pyrenochaetopsis. Although the anticancer activity the compounds 1 and 2 is associated with
cytotoxicity, a medicinal chemistry approach in future may improve their potency and selectivity.
4. Material and Methods
4.1. General Procedures
NMR spectra were recorded on a Bruker AV 600 spectrometer (600 and 150 MHz for 1H- and
13C-NMR, respectively, Bruker®, Billerica, MA, USA) or a Bruker Avance III spectrometer (500
and 125 MHz for 1H- and 13C-NMR, respectively). The residual solvent signals were used as
Mar. Drugs 2020, 18, 47 11 of 16
internal references: δH 7.26/δC 77.2 ppm (CDCl3), δH 1.94/δC 118.3 and δC 1.3 (CD3CN). 4-Dimethyl-
4-silapentane-1-sulfonic acid (DSS) was used as internal standard. High-resolution MS2 data were
recorded on a Xevo G2-XS QTof Mass Spectrometer (Waters®, Milford, MA, USA) coupled to a Waters
Acquity I-Class UPLC system). HR-ESIMS was recorded on a Bruker microTOF II-High-performance
TOF-MS system equipped with an electrospray ionization source. Solid phase extraction (SPE) was
performed on the Chromabond C18 SPE cartridges (6 mL/2000 mg, Macherey-Nagel, Duren, Germany).
HPLC separations were performed on a VWR Hitachi Chromaster system (VWR International, Allison
Park, PA, USA) consisting of a 5430 diode array detector (VWR International, Allison Park, PA, USA),
a 5310 column oven, a 5260 autosampler and a 5110 pump combined in parallel with a VWR Evaporative
Light Scattering Detector (ELSD 90). Routine HPLC separations were performed on semipreparative
(Onyx, 100 × 10 mm, Phenomenex, Torrance, CA, USA) C18 monolithic column, analytic (SeQuant®,
250 × 4.6 mm, Merck, Darmstadt, Germany) ZIC-HILIC column and analytic (SynergiTM, 4 µm,
250 × 4.6 mm, Phenomenex) polar-RP 80 Å LC column. The water used was MilliQ-water produced
by in-house Arium® Water Purification Systems (Sartorius, Germany). EtOAc, n-hexane, methanol
and acetonitrile were purchased from VWR International GmbH (Hannover, Germany). Potato extract
and dextrose that were used for culture medium were purchased from Sigma-Aldrich (Schnelldorf,
Germany) and from Merck, respectively. Agar was purchased from Applichem (Darmstadt, Germany).
(S)- and (R)-MTPA chloride were purchased from Merck. The 3D structures of compounds 1–3 were
obtained by using ChemBio3D Ultra 12.0 software (PerkinElmer, Waltham, MA, USA).
4.2. Strain Identification and Cultivation
The fungal strain was isolated from Fucus vesiculosus specimens collected in Falckenstein Beach
(54◦23′22.6′′ N, 10◦11′26.4′′ E), Kiel Fjord, Baltic Sea, Germany in December 2015 [12]. The fungus
was identified using ITS-5.8s rRNA sequencing to species level through building phylogenetic tree
(Figure 1). The evolutionary history was inferred by using the Maximum Likelihood method based
on the General Time Reversible model [31]. The percentage of trees in which the associated taxa
clustered together is shown next to the branches. Initial tree(s) for the heuristic search were obtained
automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances
estimated using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology
with superior log likelihood value. A discrete Gamma distribution was used to model evolutionary
rate differences among sites (5 categories (+G, parameter = 0.8198)). The rate variation model allowed
for some sites to be evolutionarily invariable ([+I], 37.97% sites). The tree is drawn to scale, with
branch lengths measured in the number of substitutions per site. The analysis involved 14 nucleotide
sequences. Evolutionary analyses were conducted in MEGA7 [32]. The fungal sample was deposited
at the GEOMAR-Biotech laboratory (Kiel, Germany). The strain was cultured on potato dextrose
agar (PDA: potato extract 4 g, dextrose 20 g, agar 15g for 1 L, pH 5.6). After 3 days of pre-culturing,
the conidia was inoculated in 500 mL cylindrical flasks containing 100 mL of seed medium (PDM:
potato extract 4 g, dextrose 20 g for 1 L; pH 5.6) incubated at 22 ◦C for 7 days on a rotary shaker at
120 rpm.
4.3. Extraction and Isolation
The 12 L of culture broth was partitioned with the same volume of EtOAc twice. The resulting
organic extract was evaporated in vacuo to afford light yellow oily extract (2.66 g). The crude extract
was subjected to a modified Kupchan partition to yield three subextracts, namely n-hexane (KH,
1.99 g), CHCl3 (KC, 345.4 mg) and aqueous MeOH (KM, 68.7 mg). Briefly, the crude extract was
dissolved in 500 mL aqueous methanol (90% MeOH) and partitioned against n-hexane (KH, 2 × 500 mL).
The MeOH content of the aq. MeOH phase was increased to 30% before partitioning against CHCl3
(KC, 2 × 500 mL). The KC subextract showed relatively high anticancer bioactivity against all five
cancer cell lines (>75% inhibition rate at 100 µg/mL) and was fractionated on a Chromabond C18
SPE cartridge. A 10% stepwise gradient elution with MeOH: H2O mixtures (0% to 100%) afforded 11
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fractions (fraction 0–10). Anticancer activity was tracked to fractions 5–7. The fraction 5 (92.7 mg) and
fraction 6 (13.3 mg) were combined and subjected to semi-preparative RP–HPLC, eluting with MeCN:
H2O (40% isocratic MeCN over 28 min, and gradual increase to 60% by 40 min, flow 3.0 mL/min)
to yield 7 subfractions (fraction 5.1 to 5.7). Subfraction 5.4 contained the pure compound 1 (2.4 mg,
tR 16.5 min). Fraction 5.7 (3.6 mg) was rechromatographed by RP-HPLC (isocratic mixture H2O: MeCN
(45:55, flow 1.0 mL/min) to yield 2 (1.2 mg, tR 8.0 min) and 3 (0.8 mg, tR 9.5 min). The fraction 7 (25.4 mg)
was subjected to a semi-prep. RP–HPLC (65% isocratic MeCN over 30 min, and gradual decrease
to 60% MeCN to 60%MeCN by 35 min, flow 3.0 mL/min) to yield 5 subfractions (fraction 7.1–7.5).
Fraction 7.4 (12.9 mg) was separated on HPLC equipped with an analytical HPLC column (SynergiTM,
250 × 4.6 mm, Phenomenex) using MeCN:H2O (50% isocratic MeCN over 6 min and gradual increase
to 78% MeCN by 12 min (flow 1.0 mL/min)) to yield 4 (1.4 mg, tR 6.5 min) in a pure state.
Pyrenosetin A (1): Colorless oil; [α]22D +30 (c 0.10, MeOH); IR (oil) vmax 3554, 3249, 2952, 2875, 1721, 1683,
1456, 1378, 1271 cm−1; 1H-NMR (CDCl3, 600 MHz) and 13C-NMR (CDCl3, 150 MHz), Tables 1 and 2;
HR-ESIMS found m/z [M + H]+ 430.2592, C25H36NO5, calculated for 430.2588.
Pyrenosetin B (2): Colorless oil; [α]22D +13 (c 0.10, MeOH); IR (oil) vmax 3550, 3185, 2944, 2862, 1726, 1675,
1456, 1378, 1249 cm−1; 1H-NMR (CDCl3, 600 MHz) and 13C-NMR (CDCl3, 150 MHz), Tables 1 and 2;
HR-ESIMS found m/z [M + Na]+ 452.2401 C25H35NO5Na, calculated for 452.2407.
Pyrenosetin C (3): Colorless oil; [α]22D +12 (c 0.10, MeOH); IR (oil) vmax 3559, 3259, 2952, 2858, 1726, 1683,
1451, 1369, 1253 cm−1; 1H-NMR (CDCl3, 600 MHz) and 13C-NMR (CDCl3, 150 MHz), Tables 1 and 2;
HR-ESIMS found m/z [M + H]+ 428.2434, C25H34NO5, calculated for 428.2431.
Phomasetin (4): Colorless oil; [α]22D +116 (c 0.15, CDCl3);
1H-NMR (CD3CN, 600 MHz) and 13C- NMR
(CD3CN, 150 MHz), Tables 1 and 2; HR-ESIMS found m/z [M + H]+ 414.2645, C25H36NO4, calculated
for 414.2639.
4.4. UHPLC-QToF-MS/MS Analysis and Molecular Networking
The SPE fractions derived from the KC subextract were analyzed on an ACQUITY UPLC I-Class
System coupled to the Waters® Xevo G2-XS QToF Mass Spectrometer equipped with an electrospray
ionization (ESI) source operating with a mass range of m/z 50–1600 Da. The 0.1 mg/mL MeOH solution
of each fraction was filtered through a 0.2 µm PTFE syringe filter (Carl Roth, Karlsruhe, Germany) and
then injected (injection volume: 0.2 µL) into the system that equipped with Acquity UPLC HSS T3
column (High Strength Silica C18, 1.8 µm, 100 × 2.1 mm I.D., Waters®) operating at 40 ◦C. Separation
was achieved with a binary LC solvent system controlled by MassLynx® (version 4.1) using mobile
phase A (99%) water/ 0.1 % formic acid (ULC/MS grade) and B 99.9% ACN/ 0.1% formic acid (ULC/MS
grade), pumped at a rate of 0.6 mL/ min with the following gradient: initial, 1% B; 0.0–6.0 min to 30%
B; 6.0–11.5 min to 100% B; 11.5–13.5 min 100% B, and a column reconditioning phase until 15 min.
ESI conditions were set with the capillary voltage at 0.8 kV, sample cone voltage at 40.0 V, source
temperature at 150 ◦C, desolvation temperature at 550 ◦C, cone gas flow in 50 L/h and desolvation gas
flow in 1200 L/h. MS/MS setting was a ramp collision energy (CE): low CE from 6 eV to 60 eV and high
CE from 9 eV to 80 eV. As a control, solvent (methanol) was injected. MassLynx® (Waters®, V4.1) was
used to analyze the achieved MS and MS2 data.
The raw data were converted to mzXML file format using MSConvert (version 3.0.10051, Vanderbilt
University, Nashville, TN, USA). The resulting mzXML data were processed in MZmine2 (version
2.32). Mass lists were created using the mass detection module with a noise level of 1500 counts for
MS1 and 10 counts for MS2. The chromatogram builder module was used to create peak lists with a
scan retention time from 0.01 min to 13.0 min, a minimum retention time of 0.01 min, a minimum peak
height of 10,000 counts and an m/z tolerance of 0.01 Da or 10 ppm. The peak lists were deconvoluted
using the local minimum search algorithm with the following parameters: chromatographic threshold
0.01%, search minimum in RT range 0.20, minimum relative height 0.01%, minimum absolute height
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1000 counts, minimum ratio of peak top/edge 2, peak duration range 0.01–3 min. For MS2 scan pairing,
the m/z range was set to 0.05 Da and retention time range to 0.2 min. Furthermore, the deconvoluted
peak lists were deisotoped with the following parameters: m/z tolerance 0.02 or 10 ppm, retention time
tolerance 0.01 min and maximum charge 2. The deisotoped peak lists were aligned through using
the Join aligner module with an m/z tolerance of 0.01 Da or 10 ppm and a retention time tolerance of
0.2 min. Weight for m/z and retention time were both set to 50. The aligned peak list was filtered to
exclude peaks derived from solvent and peaks with m/z lower than 125 Da. The peak ID’s were lastly
reset and the peak list was exported as mgf file for GNPS analysis. The reset peak list was exported as
CSV table file for bioactivity score analysis.
The adjusted mgf files were uploaded to GNPS for molecular networking analysis. A molecular
network was created with the feature based molecular networking work flow (https://ccms-ucsd.github.
io/GNPSDocumentation/featurebasedmolecularnetworking/) on the GNPS website (http://gnps.ucsd.
edu) [33]. The data was filtered by removing all MS/MS fragment ions within ±17 Da of the precursor
m/z. MS/MS spectra were window filtered by choosing only the top 6 fragment ions in the ±50 Da
window throughout the spectrum. The precursor ion mass tolerance was set to 0.02 Da and a MS/MS
fragment ion tolerance of 0.02 Da. A network was then created where edges were filtered to have
a cosine score above 0.65 and more than 6 matched peaks. Further, edges between two nodes were
kept in the network if and only if each of the nodes appeared in each other’s respective top 10 most
similar nodes. Finally, the maximum size of a molecular family was set to 250, and the lowest scoring
edges were removed from molecular families until the molecular family size was below this threshold.
The spectra in the network were then searched against GNPS spectral libraries. The library spectra
were filtered in the same manner as the input data. All matches kept between network spectra and
library spectra were required to have a score above 0.65 and at least 6 matched peaks. The CSV table
generated from MZmine2 (ver. 2.32) was input to R studio (version 1.1.463) to calculate the bioactivity
score based on the workflow reported by Nothias et al. [14]. The obtained bioactivity score list and
GNPS data were downloaded and imported into Cytoscape® (version 3.5.1, Institute for Systems
Biology, Seattle, WA, USA) to generate the bioactivity-based molecular networking.
4.5. Mosher’s Esterification
4.5.1. Preparation of 16-(S) MTPA Ester 6 and 16-(R)-MTPA Ester 7
To a solution of 1 (1.1 mg, 2.1 µmol) in abs. pyridine (0.3 mL), (S)-MTPA chloride (3.2 mg,
12.6 µmol) was added, and the reaction mixture was stirred at room temperature for 12 h. Subsequently
1.0 mL water was added to the reaction mixture and extracted using CH2Cl2. The organic layer was
evaporated under reduced pressure, and the residue was purified by RP-HPLC eluted with MeCN:H2O
(gradient from 50:50 to 100:0 in 10 min, 100:0 in 10 to 15 min, and from 100:0 to 50:50 in 15 to 21 min,
flow 1.0 mL/min) to afford 16-(S)-MTPA ester 6 (0.7 mg, tR 12.0 min) as a colorless oil. The 16-(R)-MTPA
ester 7 was prepared from 1 using (R)-MTPA chloride in pyridine employing the same procedure.
The 16-(R)-MTPA ester 7 (0.5 mg, tR 11.9 min) was a colorless oil. Both 6 and 7 were dissolved in CDCl3
and analysed by 1H-NMR spectroscopy.
4.5.2. Preparation of 16-(S) MTPA Ester 8 and 16-(R)-MTPA Ester 9
Compound 8 and 9, respectively, were individually prepared from 2 using either with (S)-MTPA
chloride) or (R)-MTPA chloride. The same procedure used for preparation of 6 was employed.
Both 16-(S)-MTPA ester 8 (0.3 mg, tR 11.3 min) and 16-(R)-MTPA ester 9 (0.3 mg, tR 11.2 min) were
colorless oils. They were dissolved in CDCl3 and analysed by 1H-NMR spectroscopy.
4.6. Bioactivity Assays
The crude extracts were initially tested in vitro against 5 human cancer cell lines: colorectal
adenocarcinoma cell line HT-29 (DSMZ, Braunschweig, Germany), malignant melanoma cell line
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A-375 (CLS, Eppelheim, Germany), colon cancer cell line HCT-116 (DSMZ), lung carcinoma cell line
A-549 (CLS, Eppelheim, Germany), human breast cancer line MB-231 (CLS), and the non-cancerous
human keratinocyte line HaCaT (CLS) at a concentration of 100 µg/mL. The antitumoral activity of the
crude extracts was evaluated by monitoring the metabolic activity using the CellTiterBlue Cell Viability
Assay (Promega, Mannheim, Germany). HT-29 and HaCaT cells were cultivated in RPMI medium,
A-549 and MB-231 cells in DMEM: Ham’s F12 medium (1:1) supplemented with 15 mM HEPES and
A-375 and HCT-116 cells in DMEM medium supplemented with 4.5 g/L D-Glucose and 110 mg/L
sodium pyruvate. All media were supplemented with L-Glutamine, 10% fetal bovine serum, 100 U/mL
penicillin, and 100 mg/mL streptomycin. The cultures were maintained at 37 ◦C under a humidified
atmosphere and 5% CO2. The cell lines were transferred every 3 or 4 days. For experimental procedure,
the cells were seeded in 96 well plates at a concentration of 10,000 cells per well. A stock solution of
40 mg/mL in DMSO was prepared of each extract. After 24 h incubation, the medium was removed
from the cells and 100 µL fresh medium containing the test samples was added. Each sample was
prepared in duplicate once. Doxorubicin as a standard therapeutic drug was used as positive control,
0.5% DMSO and growth media were used as controls. Following compound addition, plates were
cultured at 37 ◦C for 24 h. Afterwards, the assay was performed according to the manufacturer’s
instructions and measured using the microplate reader Tecan Infinite M200 at excitation 560 nm and
emission of 590 nm. For determination of IC50 values, a dilution series of the extracts was prepared
and tested, as described before for the crude extract. The IC50 values were calculated by Excel as
the concentration that shows 50% inhibition of the viability on the basis of a negative control (no
compound) and compared with the positive control (doxorubicin).
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